Emerging Infectious Diseases and First Responders

Connective tissue-specific stem and progenitor cells (also known asa mesenchymal stormal/stem cells or MSCs) have been the subject of clinical testing for various conditions, but the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models.

EMde-Emergency Medicine- Dermatology: Drug Eruptions: Etiology, Differential Diagnosis and Treatment; Cutaneous Infections and Infestations, Part I: Bacterial, Viral, and Fungal; Cutaneous Infections and Infestations, Part II: Parasites, Bites, and Stings.

The development of novel biotherapeutics is an essential element in generating the power to cure the incurable. With recent advances in cell and molecular biology, cell therapy has emerged as an effective means to treat a host of biological disorders. However, challenges remain for the clinical and commercial manufacturing of these advanced therapy products. Join us for this GEN webinar where we will discuss the manufacturing challenges that many researchers face as they begin to scale-out and scale-up biotherapy production. Moreover, we will discuss how the latest solutions from Corning Life Sciences can streamline bioproduction workflows and ease those cell and regenerative therapy manufacturing woes.

Today millions of patients suffer or die from diseases that will be treatable or even preventable tomorrow. For 200 years, biopharma has steadfastly produced medicines to address unmet medical needs. But in the last 20 years or so, the notion of ‘programmable medicines’ has emerged as a possibility to dramatically transform these production rates.